This guideline covers diagnosis and surgical and pharmacological treatment of women and men with early and locally advanced breast cancer. It aims to improve early identification and treatment of breast cancer to prevent disease progression and reduce deaths.
In March 2017 a new recommendation was added to section 1.6 (recommendation 1.6.9, dated 2017) after the evidence for genetic testing in women with triple negative breast cancer was reviewed.
This guideline includes recommendations on:
- referral, diagnosis and preoperative assessment of women with early and locally advanced breast cancer
- treatment with surgery to the breast and axilla
- breast reconstruction
- adjuvant treatment with endocrine therapy, chemotherapy, biological therapy and radiotherapy
- primary systemic therapy
- complications of local treatment and menopausal symptoms
Who is it for?
- Healthcare professionals
- People with early and locally advanced breast cancer and their families and carers
Is this guideline up to date?
Guideline development process
This guideline updates and replaces NICE guidance TA107 (August 2006), TA108 (September 2006) and TA109 (September 2006).
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.